Juvenile Idiopathic Arthritis comprises 7 subcategories. As the insights in pathogenesis progress so does the need for reclassification that is based more on biology than on clinical phenotypes. After a series of clinical trials for new biologicals, now trials are started that test specific treatment strategies such as treat to target an d step down studies. Especially rapid induction of remission is currently a major aim, followed by biomarked guided tapering of medication.
The expending number of potential biomarkers forms the basis for the creation of personalized medicin, a strategy aimed at providing individualized medication choices. Since most pediatric rheumatic conditions are rare, international collaboration is vital. The recently created European Reference Networks (ERN) will prove instrumental here.
Disclosure of Interest None declared